Systemic Scleroderma Treatment Market to Surpass US$ 1.99 Billion by 2028 - Coherent Market Insights

Global Systemic Scleroderma Treatment Market, By Drug Class ( Immunosuppressant, Phosphodiesterase 5 Inhibitors (PHA), Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, and Others), By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1.51 billion in 2021, and is expected to exhibit a CAGR of 4.0 %  during the forecast period (2021-2028).

Rising number of product approvals and launches is expected to drive the growth of the global systemic scleroderma treatment market during the forecast period. For instance, on March 5 2021, Roche Holding AG, a global leader in pharmaceuticals and diagnostics, announced that the U.S. Food and Drug Administration (FDA) had approved Actemra/RoActemra (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with few treatment options.

Increasing number of research collaboration between academic institutes is expected to propel the growth of the global systemic scleroderma treatment market during the forecast period. For instance, on January 19, 2021, the Scleroderma Program at University of Michigan medicine department, as well as the departments of rheumatology and dermatology, collaborated with the Northwestern University Scleroderma Program in Chicago and the Mayo Clinic to investigate the causes of disabling scarring, using human patient samples, preclinical mouse models, and explanted human skin. Scleroderma inflammation was found to significantly increase CD38, an enzyme that normally breaks down a metabolic nutrient, NAD+. When NAD+ levels fall, tissue injury becomes chronic and scar formation replaces healthy repair.

Global Systemic Scleroderma Treatment Market- Impact of Coronavirus (COVID – 19) Pandemic

The COVID-19 pandemic has affected several markets across the globe and is also expected to hamper the global systemic scleroderma treatment market. The COVID-19 pandemic has affected the demand and supply of healthcare products in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and due to its financial impact on firms and financial markets. Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit the growth of the global systemic scleroderma treatment market during the forecast period, owing to the high susceptibility of scleroderma diagnosed patients towards COVID-19 disease. For instance, according to revised statement by Scleroderma Foundation advisory board on August 1, 2021, the scleroderma, particularly if the lungs are involved, may increase one’s chances of developing a more severe form of the COVID-19 illness. Hence, individuals with scleroderma, particularly those on immunosuppressive treatments or suffering from lung disease, should strictly follow national, state, and local directives for social distancing and stay-at-home orders.

Browse 33 Market Data Tables and 25 Figures spread through 167 Pages and in-depth TOC on Global Systemic Scleroderma Treatment Market, By Drug Class (Immunosuppressant, Phosphodiesterase 5 Inhibitors (PHA), Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, and Others), By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Systemic Scleroderma Treatment Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/systemic-scleroderma-treatment-market-4641

Key Takeaways of the Global Systemic Scleroderma Treatment Market:

• The global systemic scleroderma treatment market is expected to exhibit a CAGR of 4.0% over the forecast period (2021-2028). North America is expected to account for major market share over the forecast period (2021-2028), owing to rising product launches or approvals. For instance, on December 1, 2020, Acceleron Pharma Inc., a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced that ACE-1334 had been designated as an Orphan Drug by the U.S. Food and Drug Administration (FDA) for the treatment of patients with systemic sclerosis. ACE-1334 is a TGF-beta superfamily-based ligand trap discovered by Acceleron that binds and inhibits TGF-beta 1 and 3 ligands but not TGF-beta 2.
• Some of the major players operating in the global systemic scleroderma treatment market include Boehringer Ingelheim International GmbH, Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Novartis AG, Gilead Sciences, Inc., United Therapeutics, Hoffmann La Roche Ltd., Eli Lilly and Co., and Teva Pharmaceutical Industries Ltd.